Wendy Y Chen
Publication Activity (10 Years)
Years Active: 2022-2024
Publications (10 Years): 10
Publications (10 Years): 10
Top Venues
Publications
- Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Victoria Attaya, Ibrahim M Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine M Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah Jean Ballinger, Sylvia Adams, Lisa Anne Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, José Pablo Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney
- Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M TolaneyPACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
- Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M TolaneyPACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)
- Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma L Mahtani, Cynthia X Ma, Angela M DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D Miller, Yara G Abdou, Elizabeth C Riley, Rubina Qamar, Priyanka Sharma, Sonya A Reid, Natalie Sinclair, Meredith Faggen, Caroline C Block, Naomi Y Ko, Ann H Partridge, Wendy Y Chen, Michelle DeMeo, Victoria Attaya, Amanda Okpoebo, Jillian Alberti, Yuan Liu, Eric Gauthier, Harold J Burstein, Meredith M Regan, Sara M TolaneyPACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (17) (2024)